Arbutus Biopharma (ABUS) Cash from Operations Growth (1y) (2014 - 2026)

Arbutus Biopharma (ABUS) Cash from Operations Growth (1y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (1y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 7.14%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 356.73%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 74.39%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 3.23%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Arbutus Biopharma 880.36 Mn 785.13 Mn - 39.44%

Historic Data

Download Data
DateValue
Mar 31, 2026 39.44%
Dec 31, 2025 54.63%
Sep 30, 2025 71.95%
Jun 30, 2025 -8.58%
Mar 31, 2025 30.60%
Dec 31, 2024 40.35%
Sep 30, 2024 4.81%
Jun 30, 2024 25.84%
Mar 31, 2024 29.32%
Dec 31, 2023 -1.78%
Sep 30, 2023 -16.54%
Jun 30, 2023 3.62%
Mar 31, 2023 -232.41%
Dec 31, 2022 13.34%
Sep 30, 2022 -16.56%
Jun 30, 2022 -44.86%
Mar 31, 2022 215.31%
Dec 31, 2021 -30.59%
Sep 30, 2021 -31.72%
Jun 30, 2021 -59.18%